Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab's deal to buy Iridium partly with its own stock confirms the stock is worth very little. Per @junkbondinvest, Rocket Lab is paying $8 billion in enterprise value, $54 a share, half in cash and half in Rocket Lab stock. Using an overvalued currency to buy something with real value is accretive and minimizes the loss for shareholders, following the playbook of SPCX buying Cursor. x.com  x.com 

Rocket Lab's growing Space Systems business positions it to provide more than launches for the space economy. It generated $189.5M in Q2, 81% of revenue; if its pending Iridium acquisition closes, it would gain a global satellite communications network. At about $51, this is one of the most compelling long-term opportunities in the space sector over 3-5 years, provided it keeps executing. Neutron's launch has slipped to 2027, and execution risks remain. x.com  x.com  x.com 

Rocket Lab shares look set to grind as Neutron's first flight slips, even though the core business is at its strongest. Q2 revenue hit a record $234.1M, up 62%, and backlog rose 137% to $2.356B. But the Q3 guide cuts GAAP gross margin to 29-31% from 36.1%, below the ~37.6% expected, with adjusted EBITDA losses widening to $17-23M on low-margin satellite programs, Mynaric integration and Neutron spending. A Q1 2027 Neutron debut is now the base case, which will disappoint high expectations. x.com 

Rocket Lab could face a difficult 9-12 months because much of the space industry's future is already priced into equity valuations, even as its business and backlog grow. A monthly close below the $61 21-month EMA would raise the risk that the uptrend has ended and shift attention toward $35-45 for a better long-term entry; holding $61 preserves a more constructive reading. The company could still trade considerably higher over a longer horizon. x.com 

Rocket Lab's bounce has room to run to $65 after buyers returned following shipment of Neutron's second stage to its Virginia launch site. A break above $65 before November 9 results remains the real test. x.com 

Rocket Lab's delayed Neutron first flight pushes out a key part of its planned launch capacity. Flight one has moved to 2027, at least 1.5 years later than the previously indicated timing; the lack of clearer guidance is frustrating. The stock could fall 50% if it breaks key support, though that downside is conditional. x.com  x.com  x.com 

Rocket Lab's only 'moat' was Neutron, and its reported launch delay now amounts to cancellation for the investment case. The quoted report puts its inaugural launch in 2027; $2.99 is floated as a possible share price. x.com 

Rocket Lab's 58% drop from its high on the Iridium deal financing is the entry for a five-year hold. The $8B Iridium acquisition adds a 66-satellite constellation with over $870M of annual revenue, turning a launch company into an end-to-end space business. Revenue grew 62% to $234M last quarter, backlog rose 137% to $2.36B with a record 90+ launches booked, Electron is 13 for 13 this year, and Neutron is targeted for the pad in Q4. x.com 

Rocket Lab has no reason to climb back above $100 anytime soon without a huge catalyst. Earnings were OK but nothing to rave about, and Neutron was delayed. x.com